文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

SMA-TB:评估乙酰水杨酸和布洛芬作为辅助治疗联合世界卫生组织推荐结核方案的2b期随机双盲安慰剂对照试验研究方案

SMA-TB: study protocol for the phase 2b randomized double-blind, placebo-controlled trial to estimate the potential efficacy and safety of two repurposed drugs, acetylsalicylic acid and ibuprofen, for use as adjunct therapy added to, and compared with, the standard WHO recommended TB regimen.
PubMed 文献 · Trials · 2023-06-28

SMA-TB是一项多中心随机、2b期、安慰剂对照、三臂、双盲临床试验,计划纳入354名南非和格鲁吉亚确诊肺结核成人,随机接受标准WHO推荐结核方案+安慰剂、+乙酰水杨酸或+布洛芬,旨在评估两种非甾体抗炎药作为宿主导向辅助治疗在减少组织损伤和不良结局方面的潜在疗效与安全性。

要点

  • SMA-TB为2b期随机双盲安慰剂对照三臂试验,纳入354名南非和格鲁吉亚确诊肺结核成人。
  • 干预组在标准WHO推荐结核方案基础上分别加用乙酰水杨酸或布洛芬,对照组加用安慰剂。
  • 研究旨在提供宿主导向辅助治疗的概念验证,并评估其在不同人群和药物敏感性中的适用性。

核心结论

  • SMA-TB将提供宿主导向治疗作为辅助治疗的概念验证,并识别该干预在不同人群组(不同流行病学背景和药物敏感性)中减少组织损伤和不良结局风险的适用性。

研究设计与样本

  • 多中心随机、2b期、安慰剂对照、三臂、双盲临床试验,计划纳入354名南非和格鲁吉亚确诊肺结核成人。
  • 受试者随机分为标准WHO推荐结核方案+安慰剂、标准方案+乙酰水杨酸或标准方案+布洛芬三组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The duration and regimen of tuberculosis (TB) treatment is currently based predominantly on whether the M. tuberculosis (Mtb) strain is drug-sensitive (DS) or multidrug-resistant (MDR) with doses adjusted by patients' weight only. The systematic stratification of patients for personalized treatment does not exist for TB. As each TB case is different, individualized treatment regimens should be applied to obtain better outcomes. In this scenario, novel therapeutic approaches are urgently needed to (1) improve outcomes and (2) shorten treatment duration, and host-directed therapies (HDT) might be the best solution. Within HDT, repurposed drugs represent a shortcut in drug development and can be implemented at the short term. As hyperinflammation is associated with worse outcomes, HDT with an anti-inflammatory effect might improve outcomes by reducing tissue damage and thus the risk of permanent sequelae. METHODS: SMA-TB is a multicentre randomized, phase IIB, placebo-controlled, three-arm, double-blinded clinical trial (CT) that has been designed in the context of the EC-funded SMA-TB Project ( www.smatb.eu ) in which we propose to use 2 common non-steroidal anti-inflammatory drugs (NSAID), acetylsalicylic acid (ASA) and ibuprofen (Ibu), as an HDT for use as adjunct therapy added to, and compared with, the standard of care (SoC) World Health Organization (WHO)-recommended TB regimen in TB patients. A total of 354 South African and Georgian adults diagnosed with confirmed pulmonary TB will be randomized into SoC TB treatment + placebo, SoC + acetylsalicylic acid or SoC + ibuprofen. DISCUSSION: SMA-TB will provide proof of concept of the HDT as a co-adjuvant treatment and identify the suitability of the intervention for different population groups (different epidemiological settings and drug susceptibility) in the reduction of tissue damage and risk of bad outcomes for TB patients. This regimen potentially will be more effective and targeted: organ saving, reducing tissue damage and thereby decreasing the length of treatment and sequelae, increasing cure rates and pathogen clearance and decreasing transmission rates. It will result in better clinical practice, care management and increased well-being of TB patients. TRIAL REGISTRATION: Clinicaltrials.gov NCT04575519. Registered on October 5, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Arias L, Otwombe K, Waja Z, et al. SMA-TB: study protocol for the phase 2b randomized double-blind, placebo-controlled trial to estimate the potential efficacy and safety of two repurposed drugs, acetylsalicylic acid and ibuprofen, for use as adjunct therapy added to, and compared with, the standard WHO recommended TB regimen. Trials. 2023. PMID: 37370174. doi:10.1186/s13063-023-07448-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。